

Provided by:



## Rheumatology Case Management 2023-2024

**Rheumatology Case Management 2023-2024 - 5/21/2024**

**May 21, 2024**

**9:00 AM - 10:00 AM**

**Online/Rheumatology Conference Room 5 White**

### Target Audience

This program has been designed for INTERNAL MEDICINE - Rheumatology

### Series Educational Objectives

After participating in this regularly scheduled series, participants should be able to:

- 1 Discuss interpretation of radiology results
- 2 Discuss interpretation of advanced serologic testing
- 3 Discuss prognostic implications of rheumatologic tests
- 4 Describe how to diagnose patients earlier in disease presentation
- 5 Describe adverse effects of immunosuppressive therapy
- 6 Discuss disease progression and prognosis
- 7 Discuss immunology behind rheumatologic disease

### Accreditation

In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

### Designation of Credit

**Physicians:** Penn Medicine designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Nurses:** This activity is for 1.00 contact hours.

**Pharmacists:** This activity is not approved for pharmacy contact hours

**PAs:** AAPA accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credit*<sup>™</sup> from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 1.00 Category 1 credits for completing this activity.

**Approved for (PSRM) patient safety/risk management designation**

### Acknowledgement of Commercial Support\*

None

For more information, please contact  
John Davis  
(215) 662-2792  
johdav@upenn.edu

**Check your transcript online at <https://upenn.cloud-cme.com>**

### Disclosure of Relevant Financial Relationships and Unapproved Uses of Products

It is policy at Penn Medicine Office of Continuing Medical and Interprofessional Education for individuals who are in a position to control the content of an educational activity to disclose to the learners all relevant financial relationships (RFRs) that they have with any ineligible company, which is defined as any company whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Disclosure to learners includes all RFRs for all those in control of content including faculty, planners, moderators, and reviewers.

The intent of this policy is to ensure that Penn CME/CE certified activities promote quality and safety, are effective in improving medical practice, are evidence-based, are based on valid content, and are independent of control from ineligible companies and free of commercial bias. Peer review of all content was conducted for all faculty presentations whose disclosure information was found to contain any financial relationships. Part of the peer review process involved reviewing the content, determining which financial relationships were relevant, and applying appropriate mitigation strategies. In addition, all faculty were instructed to provide balanced, scientifically rigorous and evidence-based presentations.

The staff in the Office of Continuing Medical and Interprofessional Education (CME and IPCE), have disclosed that they have no financial relationships with any ineligible companies. Any peer reviewer who is determined to have a relevant financial relationship must recuse themselves from the peer review process.

Name of individual	Individual's role in activity	Nature of Relationship(s) / Name of Ineligible Company(s)
Michael George, MD	Other Planning Committee Member	Consulting Fee-AbbVie, Inc. (Relationship has ended)  Grant or research support-Glaxo Smith Kline   Grant or research support-Janssen Pharmaceuticals (J&J)   Grant or research support-CSL Behring - 11/29/2023
Chadwick R Jehr, MD	Other Planning Committee Member	Nothing to disclose - 01/18/2024
Joshua F. Baker, MD	Other Planning Committee Member	Consulting Fee-Bristol-Myers Squibb (Relationship has ended)   Consulting Fee-CorEvitas LLC   Consulting Fee-Cumberland Pharma (Relationship has ended)   Consulting Fee-Pfizer, Inc. (Relationship has ended) - 11/29/2023
Sharon Kolasinski, MD	Other Planning Committee Member	Nothing to disclose - 12/18/2023
Steffan Schulz, MD	Other Planning Committee Member	Nothing to disclose - 01/30/2024
Anupama Shahane, MD	Course Director	Nothing to disclose - 12/19/2023
Preethi Thomas, MD	Other Planning Committee Member	Nothing to disclose - 01/28/2024
Peter A Merkel, MD	Other Planning Committee Member	Consulting Fee-AbbVie, Inc.   Grant or research support-AbbVie, Inc.   Consulting Fee-Astra Zeneca Pharmaceuticals   Grant or research support-Astra Zeneca Pharmaceuticals   Consulting Fee-Boehringer-Ingelheim   Grant or research support-

		Boehringer-Ingelheim   Consulting Fee-Bristol-Myers Squibb   Grant or research support-Bristol-Myers Squibb   Consulting Fee-Cabaletta (Relationship has ended)   Consulting Fee-CSL Behring (Relationship has ended)   Consulting Fee-Dynacure (Relationship has ended)   Consulting Fee-Genentech (Relationship has ended)   Grant or research support-Genentech (Relationship has ended)   Grant or research support-Eicos (Relationship has ended)   Grant or research support-Electra   Consulting Fee-Sanofi Genzyme (Relationship has ended)   Grant or research support-Sanofi Genzyme (Relationship has ended)   Consulting Fee-Immagine (Relationship has ended)   Consulting Fee-Janssen Pharmaceuticals (J&J) (Relationship has ended)   Consulting Fee-Kyverna   Stocks or stock options, excluding diversified mutual funds-Kyverna   Consulting Fee-Glaxo Smith Kline   Grant or research support-Glaxo Smith Kline   Consulting Fee-Inflarx GMBH   Grant or research support-Inflarx GMBH (Relationship has ended)   Consulting Fee-Magenta (Relationship has ended)   Consulting Fee-Novartis (Advanced Health Media) (Relationship has ended)   Consulting Fee-Neutrolis (Relationship has ended)   Consulting Fee-NS Pharma   Consulting Fee-Takeda Pharmaceuticals   Grant or research support-Takeda Pharmaceuticals   Consulting Fee-Pfizer, Inc. (Relationship has ended)   Consulting Fee-Q32   Consulting Fee-Regeneron Pharmaceuticals, Inc. (Relationship has ended)   Consulting Fee-Sparrow   Consulting Fee-Argenx   Consulting Fee-Vistara - 01/21/2024
Rennie Rhee, MD	Other Planning Committee Member	Nothing to disclose - 01/26/2024
Nora Sandorfi, MD	Other Planning Committee Member	Consulting Fee-Janssen Pharmaceuticals (J&J)   Advisor-Novartis / Amgen (Relationship has ended) - 12/12/2023
Carla Scanzello, MD	Other Planning Committee Member	Grant or research support-Implicit biosciences - 01/26/2024
Ethan Craig, MD, MHS	Other Planning Committee Member	Consulting Fee-Novartis (Advanced Health Media) (Relationship has ended)   Consulting Fee-Calico - 01/22/2024
Alexis Ogdie, MD	Other Planning Committee Member	Consulting Fee-Pfizer, Inc.   Grant or research support-Janssen Pharmaceuticals (J&J)   Consulting Fee-CorEvitas   Honoraria-Kopa/Twill, Gilead   Grant or research support-AbbVie, Inc.   Grant or research

		support-Novartis / Amgen   Grant or research support-Pfizer, Inc.   Consulting Fee-Janssen Pharmaceuticals (J&J)   Consulting Fee-Glaxo Smith Kline   Consulting Fee-UCB   Consulting Fee-Bristol-Myers Squibb   Consulting Fee-Novartis / Amgen   Consulting Fee-AbbVie, Inc. - 09/20/2023
Naomi Amudala, CRNP RN	Nurse Planner	Speakers Bureau-Amgen - 08/22/2023
Shubhasree Banerjee, MD	Other Planning Committee Member	Nothing to disclose - 06/16/2023
Chris Derk, MD	Other Planning Committee Member	Nothing to disclose - 12/18/2023
Jonathan Dunham, MD	Other Planning Committee Member	Nothing to disclose - 01/30/2024
Kimberly Dequattro, MD	Other Planning Committee Member	Nothing to disclose - 01/18/2024
Adam Mayer, MD	Faculty	Nothing to disclose - 08/08/2023

Relevant financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected